The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Unlocking ROI and efficiency in drug development
Explore the quantifiable benefits of end-to-end integration
Infographic
The traditional model of drug development is no match for today’s competitive environment. Handoffs to disparate disconnected providers create knowledge and service gaps that add risk and delays to processes, result in unclear accountability, and, in many cases, inflate drug development costs.
View the findings of a study by the Tufts Center for the Study of Drug Development that used real-world data to measure the value of end-to-end integration.
Findings include:
- Markedly higher ROI
- Significant projected financial value for Phase III oncology programs alone
- Remarkable time savings of nearly three years
Explore the infographic to see how the numbers stack up—and what they could mean for your program.
